ozekibart
Generic: Ozekibart·Code: INBRX-109
ozekibart: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Inhibrx Biosciences, Inc. (INBX) | Phase 2 |
FDA Decisions
FDA_MeetingInhibrx plans to meet with the FDA in the second half of 2026 to discuss an accelerated approval pathway for Ewing sarcoma if current response and duration trends continue.(INBX)
Frequently asked questions
Who is developing ozekibart?
ozekibart is being developed by Inhibrx Biosciences, Inc..
What is ozekibart's latest FDA decision?
The most recent tracked FDA decision for ozekibart is FDA_Meeting for Inhibrx plans to meet with the FDA in the second half of 2026 to discuss an accelerated approval pathway for Ewing sarcoma if current response and duration trends continue..
Get deeper analysis on ozekibart
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis